Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03212365 · ClinicalTrials.gov registry record · Phase 2
Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery
A Phase 2 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 2
- Development phase
- 295
- Enrollment target
NCT03212365 is a Phase 2 study that has completed, run by University of Utah. The registered enrollment target is 295 participants.
The verdict
NCT03212365, a Phase 2 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 295 participants
- Enrollment target
Study Summary
Plastic and reconstructive surgeons consistently create large, raw surfaces as part of their operative procedures. Thus, plastic \& reconstructive surgery patients are among those at highest risk for anticoagulant-associated bleeding adverse drug events (ADEs). This study seeks to optimize both the safety and effectiveness of post-operative enoxaparin by comparing aFXa levels, bleeding events, and VTE events among plastic \& reconstructive surgery patients randomized to receive two different enoxaparin dose regimens.
Interventions
- DRUG Fixed dose
- DRUG Variable dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2017-07-03 |
| Est. Completion | 2019-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03212365
The ClinicalTrials.gov registry entry for NCT03212365 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 295 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fixed dose is the first listed.
NCT03212365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03212365 about?
NCT03212365 is a clinical study titled "Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery". Plastic and reconstructive surgeons consistently create large, raw surfaces as part of their operative procedures. Thus, plastic \& reconstructive surgery patients are among those at highest risk for anticoagulant-associated bleeding adverse drug events (ADEs). This study seeks to optimize both the ...
What is the current status of trial NCT03212365?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 295 participants. The study started on 2017-07-03. Estimated completion is 2019-10-01.
What interventions are being tested in trial NCT03212365?
The interventions under investigation include: Fixed dose (DRUG), Variable dose (DRUG).
Who is sponsoring clinical trial NCT03212365?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.